

Pharmacy Formulary Updates for February 2018

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in February 2018:

Drug Name	Tufts Health Public Plan Formulary
	3-Tier QHP Formulary
Aliqopa	MB;PA
Brineura	MB;PA
Xadago	T3;PA
Enbrel mini	T2;PA;SP;QL
Endari	T2;PA
Nityr	T2;PA
Ximino	NC
Dovonex	T3;QL
Nutrestore	T2;PA
Jardiance	T2
Synjardy	T2
Synjardy XR	T2
glatiramer 40 mg	T2;SP;QL
esomeprazole 24hr OTC	T2
sildenafil citrate	T2;QL
Bosulif 400 mg	T2;PA;SP;QL
Intrarosa	T3
Qtern	NC
Bydureon Bcise	NC
benzoyl peroxide/hydrocortisone lotion 7.5-1%	NC
Juluca	T2
doxepin cream	T2;QL
Viread tablets	NC
Sustiva	NC
carbinoxamine maleate 6 mg tablets	T2
Verzenio	T2;PA;SP

Tracleer 32 mg tablets	T2;PA;SP
Siliq	T2;PA;SP;QL
Tremfya	T2;PA;SP;QL
Reyataz capsules	NC
atazanavir capsules	T2
Estrace 0.01% vaginal cream	NC
estradiol 0.01% vaginal cream	T2
Viagra	NC;QL
OB complete capsules	NC
methylphenidate 72 mg ER tablets	T3;PA;STPA
Xigduo XR	NC
Alunbrig 90,180 mg, Pak	T2;PA;SP
Copaxone 20, 40 mg	NC;QL

Key:

MB: Medical Benefit **QL:** Quantity Limitation
NC: Not covered **SP:** Specialty Pharmacy - provided
NTM: New-to-market through CVS/specialty
PA: Prior Authorization **ST:** Step Therapy